About MiNA Therapeutics
MiNA Therapeutics is a Healthcare company based in London (United Kingdom) founded in 2008 by Pal Saetrom, Nagy Habib, and John Rossi. Small activating RNA therapeutics are developed to restore gene function. MiNA Therapeutics has raised $460.41 million across 9 funding rounds from investors including Lilly, Boehringer Ingelheim and Nxera Pharma. The company has 37 employees. Its chief executive, as recorded, is Robert Sebastian Habib. MiNA Therapeutics offers products and services including RNAa Therapeutics and Pipeline Programs. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is MINA THERAPEUTICS LIMITED.
Company details
Developer of small activating RNA therapeutics. It develops a new class of medicines that restore or boost normal gene function, impacting protein-modulated pathways in cells. The company focuses on genetic medicine applications and collaborates with pharmaceutical companies to expand its technology platform into other therapeutic areas. A systematic approach allows for rapid development of new medicines, moving from concept to clinical trials within a short timeframe. One RNA medicine has completed clinical trials.
- Headquarters London, United Kingdom
- Employees 37
- Founders Pal Saetrom, Nagy Habib, John Rossi
- SectorsHealthcare
- Email••••••••
- Website minatx.com
- Social LinkedIn X
- Legal Name Mina Therapeutics Limited
- Date of Incorporation 07 Mar, 2008
- Jurisdiction LONDON, UNITED KINGDOM
- Annual Revenue$23.07 M (USD)839as on Dec 31, 2021
- Net Profit-$26.96 M (USD)-4681as on Dec 31, 2022
- EBITDA-$31.28 M (USD)-5520as on Dec 31, 2022
- Total Equity Funding$460.41M (USD)
in 9 rounds
- Latest Funding Round$15M (USD), Series A
Jul 2021
- InvestorsLilly
& 3 more
- Employee Count37
Products & Services of MiNA Therapeutics
MiNA Therapeutics offers a comprehensive portfolio of products and services, including RNAa Therapeutics and Pipeline Programs.
Medicines that activate genes to restore cellular functions for disease treatment.
Advancing medicines for genetic diseases through research and trials.
Funding Insights of MiNA Therapeutics
MiNA Therapeutics has successfully raised a total of $460.41M across 9 strategic funding rounds. The most recent funding activity was a Series A round of $15 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $460.41M
- Total Rounds 9
- Last Round Series A — $15M
- First Round $3.1M
(Dec 2014)
- Investors Count 4
All 9 funding rounds of MiNA Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2021 | $15M | Series A | – | – | |
| Sep 2020 | $30M | Series A | – | aMoon | – |
| May 2019 | $3.5M | Series A | – | – | – |
| Jun 2017 | $355.71M | Series A | – | Boehringer Ingelheim | – |
| Jan 2017 | $45.17M | Series A | – | Nxera | – |
| Jan 2017 | $1.63M | Series A | – | – | – |
| May 2016 | Series A | – | – | – | |
| Mar 2015 | $6.3M | Series A | – | – | – |
| Dec 2014 | $3.1M | Series A | – | – | – |
4 investors in total: 4 institutional.
Investors in MiNA Therapeutics
MiNA Therapeutics has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Boehringer Ingelheim and Nxera Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments in healthcare are focused on by aMoon. | amoon.fund | |||
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | lilly.com | United States | |
Generic drugs and clinical research services are provided globally. | 1885 | boehringer-ingelheim.com | ||
GPCR-targeted therapeutics are developed for various diseases. | 1990 | nxera.life | Tokyo, Japan |
Investor details for MiNA Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MiNA Therapeutics
17 people are tracked at MiNA Therapeutics (8 in leadership, 9 in board & advisors); the tracked headcount is 37.
| Name | Role | Group |
|---|---|---|
Pal Saetrom | Co-Founder | Leadership |
Nagy Habib | Co-Founder | Leadership |
John Rossi | Co-Founder | Leadership |
Robert Sebastian Habib | CEO | Leadership |
Robin Wright | Group Chief Financial Officer | Leadership |
Troels Koch | CTO | Leadership |
Robert Habib Mba | CEO | Leadership |
Peter Bains | Chief Business Officer | Leadership |
Antonin de Fougerolles | Scientific Advisor | Board & advisors |
Robert C. Kopple | Non Executive Director | Board & advisors |
Pål Sætrom | Co-Founder & Scientific Advisor | Board & advisors |
Hans Huber | Scientific Advisor | Board & advisors |
Declan Doogan | Scientific Advisor | Board & advisors |
Gur Roshwalb | Non Executive Director | Board & advisors |
Robert Lechler | Chairman | Board & advisors |
Deya Corzo | Member, Scientific Advisory Board | Board & advisors |
Susan Clement Davies | Director | Board & advisors |
Complete people profiles for MiNA Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of MiNA Therapeutics
3 dated milestones of MiNA Therapeutics across 13 years, from founding to its latest funding, stage changes and deals.
- Founded MiNA Therapeutics is founded.
- Funding First funding round of $3.1M.
- Funding Latest funding round, Series A, of $15.0M.
Web traffic of MiNA Therapeutics
The website of MiNA Therapeutics (minatx.com) receives about 1.7K visits a month.
- Monthly visits1.7K
▼ 44.4% vs previous month
Top companies in Genomics & Gene Therapy Platforms
2 companies that operate in the same segment as MiNA Therapeutics (Genomics & Gene Therapy Platforms) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mina Therapeutics
Complete news archive for MiNA Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MiNA Therapeutics
MiNA Therapeutics was founded in 2008 and raised its 1st funding round 6 years after it was founded.
MiNA Therapeutics is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Robert Sebastian Habib is the CEO of MiNA Therapeutics, as recorded in our data.
MiNA Therapeutics is a funded company, having raised a total of $460.41M across 9 funding rounds to date. The company's 1st funding round was a Series A of $3.1M, raised on Dec 2014.
MiNA Therapeutics has 37 employees.
Annual revenue of MiNA Therapeutics is $23.07M as on Dec 31, 2021.
Developer of small activating RNA therapeutics. It develops a new class of medicines that restore or boost normal gene function, impacting protein-modulated pathways in cells. The company focuses on genetic medicine applications and collaborates with pharmaceutical companies to expand its technology platform into other therapeutic areas. A systematic approach allows for rapid development of new medicines, moving from concept to clinical trials within a short timeframe. One RNA medicine has completed clinical trials.
MiNA Therapeutics offers RNAa Therapeutics and Pipeline Programs.
MiNA Therapeutics has 4 investors. Key investors include Lilly, Boehringer Ingelheim, Nxera Pharma, and aMoon.
MiNA Therapeutics operates through Mina Therapeutics Limited.